[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.0.26. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 453
Citations 0
Comment & Response
July 12, 2016

Vaccine Pricing and US Immunization Policies

Author Affiliations
  • 1Yale School of Public Health, New Haven, Connecticut
JAMA. 2016;316(2):226. doi:10.1001/jama.2016.6307

To the Editor Dr Meissner1 explored the consequences of vaccine pricing and costs for US immunization policy. New vaccines against serogroup B meningococcal disease, an extremely serious but rare condition, demonstrate the challenges government advisors face fulfilling their dual responsibilities of evaluating scientific and clinical evidence and of considering economic factors when developing vaccination recommendations.2 Because of the high costs of these vaccines and the small number of hospitalizations and deaths they could prevent, Meissner suggests that the US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) should recommend against their use instead of its current Category B (“permissive”) recommendation that encourages joint decision making by clinicians and patients on a case-by-case basis.

First Page Preview View Large
First page PDF preview
First page PDF preview
×